FIN-211, an Investigational Microbiome Therapeutic for Autism - Mark Smith PhD, Finch @Synchrony2021

Mark Smith, PhD is the Chief Executive Officer and co-founder of Finch Therapeutics, a company developing novel microbiome drugs to serve patients with serious unmet needs. Mark has led much of the seminal work on engineering the human microbiome, publishing in leading journals such as Nature and New England Journal of Medicine. He translated microbiota transplantation from a topic of research into clinical practice by founding OpenBiome, where he pioneered the universal donor model as a safe, effective and cost-efficient solution to the C. difficile epidemic.

OpenBiome has now treated more than 55,000 patients through a network of over 1,200 hospitals. He co-founded Finch Therapeutics to develop and scale a new generation of microbiome therapeutics. Mark graduated from Princeton University with a BA in Biology and received his PhD in Microbiology from MIT.

#microbiome #gut #gastrointestinal #gutbrainaxis #gutmicrobiome #microflora


🎥 This talk was part of Synchrony 2021 Online Symposium - 'From Bench to Biopharma', organised by the The BRAIN Foundation in partnership with UC Davis MIND Institute and CalTech.

🎥 For more Synchrony 2021 talks and highlights:
   • Synchrony Symposium 2021 - From Bench...  


🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

Synchrony https://synchronysymposium.com/ is the first and only international symposium on translational research in #autism, that brings together academia, #biotech, pharmaceutical companies and #venture partners from around the world with the mission to improve health and quality of life of people with #autismspectrumdisorder.

🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

The BRAIN Foundation https://brainfoundation.org/ is a 501c(3) non-profit. The founders of BRAIN envision a world where every child and adult on the autism spectrum is healthy, participates fully in education and employment, and has a better quality of life. It aims to catalyze research that results in evidence-based interventions for the disabilities associated with autism, and also results in better medical standard of care.

To accomplish this, it funds impactful research through #philanthropy and our network of partners in the venture, corporate, and grassroots community.